PURPOSE: Main objective of this study is to assess and evaluate resource use in outpatient treatment of cystic fibrosis (CF) in Germany and to compare this with current reimbursement. METHODS: Outpatient treatment was evaluated in seven different CF centers.Clinical patient data, resource use, and time consumption were recorded in 2006. A micro-costing approach was used to price resource use data. RESULTS: Mean costs of 488 Euros per patient (n = 326) and quarter occurred. Remuneration (252 Euros per patient/quarter) covered only 52% of the total costs. Furthermore, a considerable time and financial burden for patients as well as decreasing quality of life with increasing age were found. Costs for medication came to 21,604 Euros per patient/year. CONCLUSION: Human resources in German CF centers today already are below the requirements set by the European consensus for standards of CF care. It will be crucial in assuring a high level of patient care to reach a cost-covering reimbursement scheme in Germany.
PURPOSE: Main objective of this study is to assess and evaluate resource use in outpatient treatment of cystic fibrosis (CF) in Germany and to compare this with current reimbursement. METHODS:Outpatient treatment was evaluated in seven different CF centers.Clinical patient data, resource use, and time consumption were recorded in 2006. A micro-costing approach was used to price resource use data. RESULTS: Mean costs of 488 Euros per patient (n = 326) and quarter occurred. Remuneration (252 Euros per patient/quarter) covered only 52% of the total costs. Furthermore, a considerable time and financial burden for patients as well as decreasing quality of life with increasing age were found. Costs for medication came to 21,604 Euros per patient/year. CONCLUSION:Human resources in German CF centers today already are below the requirements set by the European consensus for standards of CF care. It will be crucial in assuring a high level of patient care to reach a cost-covering reimbursement scheme in Germany.
Authors: M F Wildhagen; J B Verheij; J G Verzijl; H B Hilderink; L Kooij; T Tijmstra; L P ten Kate; J Gerritsen; W Bakker; J D Habbema; F Habbema Journal: Thorax Date: 1996-03 Impact factor: 9.139
Authors: M F Wildhagen; J B Verheij; J G Verzijl; J Gerritsen; W Bakker; H B Hilderink; L P ten Kate; T Tijmstra; L Kooij; J D Habbema Journal: Eur Respir J Date: 1996-11 Impact factor: 16.671
Authors: Marie-Luise Manow; Nesrin Paulsen; Meike Rybczynski; Thomas Mir; Alexander M J Bernhardt; Hendrik Treede; Gunda Ohm; Bettina Fuisting; Uwe Rehder; Florian Meier; Marina Vogler; Thomas Meinertz; Karin Overlack; Yskert von Kodolitsch Journal: Med Klin (Munich) Date: 2010-09-08